LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average analyst rating of "Hold", with three hold ratings and two buy ratings from brokerages.
• The company's shares opened at $95.62, experiencing a 1.5% decrease in trading, while its market capitalization stands at $2.16 billion.
• LeMaitre Vascular reported $0.60 earnings per share for the last quarter, slightly exceeding analysts' expectations, and has set a guidance for FY 2025 of 2.230-2.370 EPS.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $97.60.

Several equities analysts have recently issued reports on LMAT shares. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research note on Wednesday, August 6th.

Insider Buying and Selling

In other news, Director David B. Roberts sold 10,815 shares of the firm's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares of the company's stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bridget A. Ross sold 2,500 shares of the firm's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of the business. Advisors Asset Management Inc. boosted its position in LeMaitre Vascular by 3.0% during the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier's stock valued at $341,000 after purchasing an additional 118 shares during the last quarter. Federated Hermes Inc. raised its holdings in LeMaitre Vascular by 0.4% during the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier's stock valued at $3,294,000 after buying an additional 155 shares in the last quarter. Johnson Investment Counsel Inc. raised its holdings in LeMaitre Vascular by 0.7% during the second quarter. Johnson Investment Counsel Inc. now owns 29,639 shares of the medical instruments supplier's stock valued at $2,462,000 after buying an additional 211 shares in the last quarter. Franklin Resources Inc. raised its holdings in LeMaitre Vascular by 1.6% during the second quarter. Franklin Resources Inc. now owns 13,499 shares of the medical instruments supplier's stock valued at $1,121,000 after buying an additional 212 shares in the last quarter. Finally, Avantax Advisory Services Inc. raised its holdings in LeMaitre Vascular by 1.5% during the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier's stock valued at $1,261,000 after buying an additional 229 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Stock Performance

LMAT traded up $0.63 during trading hours on Wednesday, hitting $92.92. The company's stock had a trading volume of 19,231 shares, compared to its average volume of 186,881. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.10 billion, a PE ratio of 45.11, a PEG ratio of 2.37 and a beta of 0.79. The company has a 50-day simple moving average of $89.69 and a 200 day simple moving average of $85.84.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. During the same period last year, the firm earned $0.52 EPS. The firm's revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.